Patent ID: 9642907
Date: 2017-05-09
CPC Classifications: A61K,A61P,C12N

Claim:
1. A stabilized liquid rotavirus vaccine composition consisting essentially of: a live viral antigen rotavirus 116E or I321; a first protein that is human serum albumin (HSA) at a concentration of 0.1% to 0.45%, wherein the first protein does not include recombinant human albumin; a second protein which is at least partially hydrolyzed lactalbumin hydrolyzate at a concentration between 0.01% to 0.5%; a combination of three different disaccharides selected from the group consisting of a first disaccharide combination consisting of one primary sugar sucrose at a concentration of 40% (w/v) to 55% (w/v) and two secondary sugars trehalose and maltose, each secondary sugar is present at a concentration of 0.5% (w/v), and a second disaccharide combination consisting of one primary sugar sucrose at a concentration of 40% (w/v) to 55% (w/v) and two secondary sugars lactose and maltose, each secondary sugar is present at a concentration of 0.5% (w/v); and, a buffer to adjust the pH of said composition to a value between 6.8 and 7.8, wherein the buffer is a phosphate-citrate buffer, wherein the concentration of phosphate is used at 310 mM and the concentration of citrate is used at 100 mM, wherein the buffer does not include succinate and sodium citrate; wherein said rotavirus is at a titer ranging from 10